NCT06034964View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

November 1, 2022

Study Completion Date

November 1, 2025

Conditions
TislelizumabChemotherapyFirst-lineGastric Cancer Stage IV
Interventions
DRUG

Tislelizumab

Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity

Trial Locations (1)

Unknown

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER